Bidirectional translational research: Progress in understanding addictive diseases
about
Dose preference and dose escalation in extended-access cocaine self-administration in Fischer and Lewis rats.Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer ratsProopiomelanocortin (POMC) expression and conditioned place aversion during protracted withdrawal from chronic intermittent escalating-dose heroin in POMC-EGFP promoter transgenic mice.Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviorsPharmacotherapy in the treatment of addiction: methadone.Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processingNext generation effects of female adolescent morphine exposure: sex-specific alterations in response to acute morphine emerge before puberty.Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal.Enhanced anxiety in the male offspring of sires that self-administered cocaine.Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors.Translational health research: perspectives from health education specialists.OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV.Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
P2860
Q30496229-82D0574F-DE08-4D58-9497-8832A422451CQ30514193-0D0073E4-EDB4-481A-9BC0-938583892403Q30537552-75C35C37-72ED-40A3-81F1-AFCE60DBA53EQ33643136-64E3B62F-96A0-483C-9BC2-13B456C859EEQ33643281-512F01CB-0429-43BD-A955-D7A6F090F110Q33914167-CA650758-6396-4A10-838E-3F4AE955B114Q34397442-081D35D9-3C74-4768-9C9F-AB0CC6D3632DQ34731409-D91149E2-5DDF-46FD-8F33-9C139D08BBAEQ35645517-FE9FEF1D-92B4-423D-9D8E-0F3D1463399AQ36225911-82BA97DB-CE75-46D7-85E7-5B0A569A2C50Q36389121-1DC3F43B-D436-4992-9FD3-96DA42EDAAE4Q36578300-621EE5C3-4E01-4FEE-A85A-FFF8F3F757FFQ37012052-226E3526-3F3D-4830-A837-0155C617712EQ37160674-756EB26B-5255-4165-B403-3FC14FF76342Q37589122-FA9FF8D3-2686-438D-88BD-6E58C8BD5EE1
P2860
Bidirectional translational research: Progress in understanding addictive diseases
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bidirectional translational research: Progress in understanding addictive diseases
@en
Bidirectional translational research: Progress in understanding addictive diseases.
@nl
type
label
Bidirectional translational research: Progress in understanding addictive diseases
@en
Bidirectional translational research: Progress in understanding addictive diseases.
@nl
prefLabel
Bidirectional translational research: Progress in understanding addictive diseases
@en
Bidirectional translational research: Progress in understanding addictive diseases.
@nl
P2093
P2860
P1433
P1476
Bidirectional translational research: Progress in understanding addictive diseases
@en
P2093
D A Nielsen
E R Butelman
S D Schlussman
P2860
P356
10.1016/J.NEUROPHARM.2008.07.042
P478
56 Suppl 1
P577
2008-08-07T00:00:00Z